A driver or a passenger? D421-caspase cleaved tau is associated with aggregated and insoluble tau by unknown
POSTER PRESENTATION Open Access
A driver or a passenger? D421-caspase cleaved tau
is associated with aggregated and insoluble tau
Yolanda Gibson, Katya Garn, Clare Hardy, Manuela Piarulli, Sarah Glover, Mark Ward, Emily McNaughton,
Michael Hutton, Michael O’Neill, Joanna Wolak*
From Molecular Neurodegeneration: Basic biology and disease pathways
Cannes, France. 10-12 September 2013
Background
Aggregation of tau is one of the main hallmarks of
Alzheimer’s disease and other tauopathies. Normally tau
regulates microtubule (MT) dynamics and hence axonal
function but in AD hyperphosphorylated, misfolded and
aggregated tau has reduced interaction with microtubules.
There is growing evidence that the proteolytic processing
of tau may play a crucial role in the aberrant change of
tau conformation and its aggregation. rTg4510 mice
express the human four-repeat tau gene lacking the
amino-terminal sequence (0N4R) and with a P301L
mutation. Between four and ten months of age the mice
develop progressive tau pathology and eventually neuronal
loss. The aim of this work was to investigate the impor-
tance of tau cleavage at D421, the cleavage epitope for
caspase-3 and caspase-6, and its role in tau aggregation.
We ran a longitudinal study to measure the level and
distribution of D421-caspase cleaved tau in rTg4510
between two and eight months of age to determine
whether there is a correlation between the cleavage of tau
and its conformational change.
Material and methods
Total tau and D421-caspase cleaved tau levels in the
cortex and hippocampus in each age group were
quantified using a panel of proprietary AlphaScreen
assays and by standard IHC methods. Tau aggregation
was assessed using high-speed centrifugation of brain
homogenates.
Results
The biochemical and immunohistochemical analyses of
rTg4510 showed a time-dependent increase of caspase-
cleaved tau at D421 in the cortex and hippocampus
between four and eight months of age and importantly
caspase-cleaved tau was shown to be associated with the
insoluble fraction of tau. These changes are concomitant
with progression of tau pathological changes previously
observed in this model.
Conclusions
Caspase-cleaved tau at D421 is associated with aggre-
gated and insoluble tau. Our findings contribute to the
discussion on whether therapeutics aimed at inhibiting
caspase-mediated tau cleavage could be beneficial in
slowing cleavage and aggregation, and hence potentially
inhibit the pathological cascade in Alzheimer’s disease.
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